P Unge
Overview
Explore the profile of P Unge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kimura K, Sipponen P, Unge P, Ekstrom P, Satoh K, Hellblom M, et al.
Scand J Gastroenterol
. 2017 Apr;
38(5):491-497.
PMID: 28443767
Background: The natural course of Helicobacter pylori gastritis may vary between different ethnic groups. Gastric histopathology and the occurrence of H. pylori organisms in the stomach were investigated in healed...
2.
Kimura K, Sipponen P, Unge P, Ekstrom P, Satoh K, Hellblom M, et al.
Scand J Gastroenterol
. 2003 Jun;
38(5):491-7.
PMID: 12795458
Background: The natural course of Helicobacter pylori gastritis may vary between different ethnic groups. Gastric histopathology and the occurrence of H. pylori organisms in the stomach were investigated in healed...
3.
Unge P, Kimura K, Sipponen P, Ekstrom P, Satoh K, Hellblom M, et al.
Scand J Gastroenterol
. 2003 Jun;
38(5):482-90.
PMID: 12795457
Background: As a consequence of gastric histological differences, Japanese and Swedish peptic ulcer (PU) patients may respond differently to Helicobacter pylori eradication therapies. Methods: The study was single-blind and compared...
4.
Bolling-Sternevald E, Lauritsen K, Aalykke C, Havelund T, Knudsen T, Unge P, et al.
Scand J Gastroenterol
. 2003 Jan;
37(12):1395-402.
PMID: 12523588
Background: Functional dyspepsia (FD) is defined as persistent or recurrent pain/discomfort centred in the upper abdomen, where no structural explanation for the symptoms is found. The role of drug treatment...
5.
Lindgren S, Lofberg R, Bergholm L, Hellblom M, Carling L, Ung K, et al.
Scand J Gastroenterol
. 2002 Jul;
37(6):705-10.
PMID: 12126250
Background: Glucocorticosteroid enemas are equally effective as 5-ASA enemas in the treatment of active distal ulcerative colitis (UC). With the introduction of budesonide, the risk of systemic side effects may...
6.
Malfertheiner P, OConnor H, Genta R, Unge P, Axon A
Aliment Pharmacol Ther
. 2002 May;
16 Suppl 3:1-10.
PMID: 12000312
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer....
7.
Megraud F, Lehn N, Lind T, Bayerdorffer E, OMorain C, Spiller R, et al.
Antimicrob Agents Chemother
. 1999 Oct;
43(11):2747-52.
PMID: 10543758
Culture and susceptibility testing of Helicobacter pylori strains was performed in a large multinational, multicenter randomized clinical trial. Culture was carried out on gastric biopsy samples obtained from 516 patients...
8.
Unge P
Eur J Gastroenterol Hepatol
. 1999 Sep;
11 Suppl 2:S9-17; discussion S23-4.
PMID: 10503817
Objective: In three studies, the two most successful regimens in the MACH1 study (omeprazole-amoxycillin-clarithromycin (OAC) and omeprazole-metronidazole-clarithromycin (OMC)) were investigated further. Design: Double-blind, randomized, international, multi-centre studies with parallel groups....
9.
Malfertheiner P, Bayerdorffer E, Diete U, Gil J, Lind T, MISIUNA P, et al.
Aliment Pharmacol Ther
. 1999 Jun;
13(6):703-12.
PMID: 10383498
Aims: To study the efficacy of omeprazole triple therapy in the eradication of Helicobacter pylori in patients with active gastric ulcer, and to assess healing and relapse of gastric ulcer....
10.
Zanten S, Bradette M, Farley A, Leddin D, Lind T, Unge P, et al.
Aliment Pharmacol Ther
. 1999 Apr;
13(3):289-95.
PMID: 10102960
Aim: To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active...